977 Results for "

H3

" in MedChemExpress (MCE) Product Catalog:
Products (977)

977 Results for "H3" in MCE Product Catalog:

65
65 Publications Verification
Cat. No.: HY-15648F
CAS No.: 1797983-09-5
Purity:  99.01%
Target:  

Histone Demethylase

Research Areas:  

Cancer

GSK-J4 hydrochloride is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC50s of 8.6 and 6.6 μM, respectively. GSK-J4 hydrochloride inhibits LPS-induced TNF-α production in human primary macrophages with an IC50 of 9 μM. GSK-J4 hydrochloride is a cell permeable proagent of GSK-J1 [3].
loading...
    loading...
65
65 Publications Verification
Cat. No.: HY-15648B
CAS No.: 1373423-53-0
Purity:  99.64%
Research Areas:  

Cancer

GSK-J4 is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC50s of 8.6 and 6.6 μM, respectively. GSK-J4 inhibits LPS-induced TNF-α production in human primary macrophages with an IC50 of 9 μM. GSK J4 is a cell permeable proagent of GSK-J1 [3]. GSK-J4 induces endoplasmic reticulum stress-related apoptosis .
loading...
    loading...
54
54 Cited Publications
Cat. No.: HY-123606
CAS No.: 1652629-23-6
GSK484 is a PAD4 inhibitor that effectively inhibits protein citrullination and the formation of neutrophil extracellular traps (NETs) by blocking the catalytic activity of PAD4. GSK484 suppresses the production of histone H3, MHC-I expression, CD8 + T cell activation, proliferation and inflammatory cytokine release. GSK484 reduces inflammation and bone destruction in collagen-induced rheumatoid arthritis, alleviates pain and mast cell activation in sickle cell disease, and improves myocardial ischemia-reperfusion injury and experimental colitis. In addition, GSK484 restores intestinal microbial homeostasis by reversing ferroptosis-induced dysbiosis. GSK484 can be used to study the disease mechanisms of rheumatoid arthritis, sickle cell disease, thrombosis, myocardial injury, colitis and other conditions [3] .
loading...
    loading...
49
49 Cited Publications
Cat. No.: HY-13317
CAS No.: 196618-13-0
Purity:  99.94%
Synonyms: GS 4104
Target:  

Influenza Virus

Research Areas:  

Infection Cancer

Oseltamivir (GS 4104) is an orally active influenza virus neuraminidase inhibitor (NAI). Oseltamivir inhibits influenza A/H3N2, A/H1N2, A/H1N1, and B viruses with mean IC50s of 0.67, 0.9, 1.34 and 13 nM, respectively .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-15648
CAS No.: 1373422-53-7
Purity:  99.89%
Target:  

Histone Demethylase

Research Areas:  

Cancer

GSK-J1, a chemical probe, is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with IC50 of 60 nM towards KDM6B.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-15648D
CAS No.: 2309668-29-7
Purity:  98.33%
Target:  

Histone Demethylase

Research Areas:  

Cancer

GSK-J1 lithium salt is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with IC50 of 60 nM towards KDM6B.
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-101117
CAS No.: 2083627-02-3
Purity:  99.56%
Research Areas:  

Cancer

EED226 is a polycomb repressive complex 2 (PRC2) inhibitor, which binds to the K27me3-pocket on embryonic ectoderm development (EED) and shows strong antitumor activity in xenograft mice model . EED226 is a potent, selective, and orally bioavailable EED inhibitor . EED226 inhibits PRC2 with an IC50 of 23.4 nM when the H3K27me0 peptide is used as a substrate in the in vitro enzymatic assays [3].
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-16993
CAS No.: 1801787-56-3
Target:  

Apoptosis WDR5

Research Areas:  

Cancer

OICR-9429, a chemical probe, is high affinity WD repeat domain 5 (WDR5) inhibitor, competitively blocks WDR5 interaction with MLL protein via binding the central peptide-binding pocket of WDR5. OICR-9429 can suppress histone H3K4 trimethylation and can be used for the research of various cancers including non-MLL-rearranged leukaemia, colon, pancreatic, prostate cancer and bladder cancer (BCa) .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-100421
CAS No.: 1628208-23-0
Purity:  98.31%
Target:  

Histone Demethylase

Research Areas:  

Cancer

CPI-455 is a specific, pan-KDM5 inhibitor with an IC50 of 10 nM for KDM5A. CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-100421A
CAS No.: 2095432-28-1
Target:  

Histone Demethylase

Research Areas:  

Cancer

CPI-455 hydrochloride is a specific, pan-KDM5 inhibitor with an IC50 of 10 nM for KDM5A. CPI-455 hydrochloride mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-18935
CAS No.: 1197996-80-7
Synonyms: Curaxin 137; CBL-C137
Research Areas:  

Cancer

CBL0137, a curaxin compound, is a histone chaperone facilitates chromatin transcription (FACT) inhibitor. CBL0137 downregulates NF-κB and activates p53. CBL0137 restores both histone H3 acetylation and trimethylation. CBL0137 is an anticancer agent. CBL0137 induces cancer cell apoptosis .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-129039
CAS No.: 778649-18-6
Purity:  99.58%
Synonyms: MB-3
Butyrolactone 3 (MB-3) is a specifical small-molecule inhibitor of the histone acetyltransferase Gcn5 (IC50=100 μM), which has a high affinity to the Gcn5 enzyme comparable to that of its natural substrate, histone H3. Butyrolactone 3 shows weak inhibitory on CBP (IC50=0.5 mM). Butyrolactone 3 can be used in studies of cancer, metabolic, autoimmune and neurological diseases [3].
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-15227
CAS No.: 1338466-77-5
Purity:  99.00%
EPZ004777 is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 can be used for the study of leukemia [3].
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-15227A
CAS No.: 1380316-03-9
Purity:  99.46%
EPZ004777 hydrochloride is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 hydrochloride reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 hydrochloride selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 hydrochloride can be used for the study of leukemia [3].
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-12970
CAS No.: 1700663-41-7
Purity:  98.07%
EPZ020411 is a selective, blood-brain barrier-permeable PRMT6 inhibitor with an IC50 of 0.010 μM. EPZ020411 blocks PRMT6-mediated histone H3R2 methylation, reduces ROS production, and inhibits Apoptosis. EPZ020411 is applicable to research related to neuropathic pain, colorectal cancer, ototoxicity, hearing loss and glioblastoma [3] .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-12970A
CAS No.: 2070015-25-5
Purity:  98.15%
EPZ020411 hydrochloride is a selective, blood-brain barrier-permeable PRMT6 inhibitor with an IC50 of 0.010 μM. EPZ020411 hydrochloride blocks PRMT6-mediated histone H3R2 methylation, reduces ROS production, and inhibits Apoptosis. EPZ020411 hydrochloride is applicable to research related to neuropathic pain, colorectal cancer, ototoxicity, hearing loss and glioblastoma [3] .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-102047B
CAS No.: 2448475-08-7
Purity:  98.11%
Target:  

Histone Demethylase

Research Areas:  

Cancer

KDOAM-25 citrate is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC50s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 citrate increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-15217
CAS No.: 1333377-65-3
Purity:  96.71%
Target:  

Haspin Kinase

Research Areas:  

Cancer

CHR-6494 is a potent inhibitor of haspin, with an IC50 of 2 nM. CHR-6494 inhibits histone H3T3 phosphorylation. CHR-6494 can be used in the research of cancer .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-120400
CAS No.: 1596348-32-1
Purity:  97.08%
Target:  

Histone Demethylase

Research Areas:  

Cancer

KDM5-C70 is an ethyl ester derivative of KDM5-C49 and a potent, cell-permeable and pan-KDM5 histone demethylase inhibitor. KDM5-C70 has an antiproliferative effect in myeloma cells, leading to genome-wide elevation of H3K4me3 levels .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-100818
CAS No.: 1448169-71-8
Purity:  99.65%
Synonyms: TAS-120
Target:  

FGFR

Research Areas:  

Cancer

Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM) [3].
loading...
    loading...